SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Follow-up) — Jack London

PatientJack London
Date of birth1987-01-12
IdentifiersMRN HR-ET010-SYN; SSN (made up) 000-10-4482
Document date2026-10-13
AuthorEleanor Whitcombe-Ibe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Ten-week review. [S]

History of Present Illness

Mr. London has had no alcohol for six weeks, since the evening of the ankle sprain. He takes naltrexone and losartan 100 mg every morning; he has had no dizziness. His home readings average 124/78. He eats two meals a day now, and has not missed a meal or been unwell for weeks. The ankle has healed and he is riding again. He writes every morning and has finished a long story. He has kept up weekly counseling. [S]

ElementDetail
AlcoholNone for six weeks; PEth 8 ng/mL
Potassium and creatinine5.0 mmol/L; 1.95 mg/dL (eGFR 44) four weeks after losartan 100 mg
Home readingsAverage 124/78 mmHg
AnkleHealed

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; eating regularly
CardiovascularNegativeNo dizziness or ankle swelling
GenitourinaryNegativeNo urinary or genital symptoms
PsychiatricNegativeMood good; cravings rare; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intakeOne tablet by mouth twice a day, self-directedOral route2024-08-01 to 2026-08-04stoppedS
Losartan 50 mg oral tablet once dailyOne tablet by mouth every morningOral route2026-08-04 to 2026-09-15completedS
Losartan 100 mg oral tablet once dailyOne tablet by mouth every morningOral route2026-09-15activeS
Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone checkUp to one capsule four times a day on day 1, tapering to one a day by day 4; stop after day 5; no alcohol or drivingOral route2026-08-04 to 2026-08-08completedS
Thiamine 100 mg oral tablet once dailyOne tablet by mouth dailyOral route2026-08-04activeS
Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxenOne to two tablets by mouth every six hours as needed; no more than four tablets a dayOral route2026-08-04activeS
Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicinesOne tablet by mouth every morningOral route2026-08-18activeS
Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once dailyOne tablet by mouth dailyOral route2026-09-15activeS
Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgeryOne tablet by mouth every morning; sick-day rules in writingOral route2026-10-13activeS
Diclofenac 1% gel, 4 g rubbed into the outer right ankle four times a day for up to seven days, in place of any oral anti-inflammatory medicineApply 4 g to the ankle four times a day for up to seven daysTopical route2026-09-01 to 2026-09-08completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-13Body height173cmS
2026-10-13Body weight81.4kgS
2026-10-13Body mass index (BMI) [Ratio]27.2kg/m2S
2026-10-13Systolic blood pressure126mm[Hg]S
2026-10-13Diastolic blood pressure80mm[Hg]S
2026-10-13Heart rate72/minS
2026-10-13Respiratory rate14/minS
2026-10-13Body temperature36.6CelS
2026-10-13Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-13Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-13Potassium [Moles/volume] in Serum or Plasma5mmol/L3.5-5.1 mmol/LNormalS
2026-10-13Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-10-13Creatinine [Mass/volume] in Serum or Plasma1.95mg/dL0.74-1.35 mg/dLHighS
2026-10-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M44mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
2026-10-13Phosphatidylethanol [Mass/volume] in Blood8ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingNormalS

Physical Exam

Vital signs recorded on 2026-10-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 126/80, pulse 72; weight 81.4 kg
CardiovascularRegular rhythm; no edema
MusculoskeletalRight ankle normal

Problems

ProblemClinical statusVerificationCodeProvenance
Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultationresolvedconfirmed R94.4S — Synthetic presenting problem anchored to the documented kidney damage found in 1913; superseded when the consultation staged chronic kidney disease.
Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney diseaseactiveconfirmed N18.32S — Synthetic modern diagnosis made at the consultation, anchored to his documented kidney damage and death from uraemia; the cause in the modern episode is synthetic and is not a claim about his real kidneys.
Hypertensive chronic kidney disease, untreated until intakeactiveconfirmed I12.9S — Synthetic modern diagnosis made at the consultation.
Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mLactiveconfirmed F10.20S — Synthetic modern diagnosis anchored to his own published account of heavy drinking; the criteria, scores and amounts are synthetic and are not a claim about his real drinking.
Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intakeactiveconfirmed K70.0S — Synthetic finding of the ultrasound and elastography at the consultation; not a claim about his real liver.
Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its placeresolvedconfirmed Z79.1S — Synthetic medication history; the joint pain is anchored to the documented rheumatism of 1914, which is not given a diagnosis.
Cigarette smoking, about ten a day; not ready to stop while he stops drinkingactiveconfirmed F17.210S — Synthetic tobacco use; a physician-author's suggestion of heavy tobacco use is recorded only as a retrospective claim.
Right ankle sprain (lateral ligaments, moderate), from stepping into a burrow while walking the pasture; Ottawa ankle rules negative; healed in about four weeksresolvedconfirmed S93.401AS — Synthetic acute injury; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationStandardized office blood pressure (five minutes' rest, validated device, average of readings)Every visitCompleted today126/80 mmHg; home average 124/78
LaboratoryPotassium and creatinine after starting or changing losartan or an SGLT2 inhibitorTwo to four weeks after each start or changeCompleted todayFour weeks after losartan 100 mg: potassium 5.0 mmol/L, creatinine 1.95 mg/dL; dapagliflozin started today, recheck in two weeks
LaboratoryCreatinine with eGFR and urine albumin-to-creatinine ratioG3b A2: twice a year, and at each medicine checkCompleted todayeGFR 44; urine albumin due at twelve weeks
LaboratoryElectrolytes and bicarbonateWith each kidney testCompleted todaySodium 139; bicarbonate 23 mmol/L
Medication safetySGLT2 inhibitor safety: sick-day rules, ketoacidosis, genital infection, volumeAt the start and every visitCompleted todayStarted today after six weeks of abstinence and regular meals; sick-day rules in writing; genital hygiene explained
Medication safetyMedication reconciliation: no NSAIDs, kidney dosing, contrast safetyEvery visitCompleted todayNo NSAIDs; dapagliflozin added
Self-managementLifestyle: sodium below 2 g a day, activity, diet, weightEvery visitCompleted todayRiding and swimming; less salt
SurveyDrinking since the last visit (self-report)Every visitCompleted todayNone for six weeks
LaboratoryPEthAt baseline and every four to six weeks in early recoveryCompleted today8 ng/mL: abstinence
LaboratoryLiver tests (AST, ALT, GGT) on naltrexoneAt baseline, at four to six weeks, then every few monthsUp to dateNormal-range at six weeks; next at twelve weeks
Medication safetyNaltrexone safety: opioid use, nausea, wallet cardEvery visitCompleted todayNo nausea; no opioid
ReferralAddiction-focused counseling and mutual helpWeekly in early recoveryCompleted todayWeekly sessions kept
SurveySuicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; firearms locked; 988 card carried
Self-managementTobacco use and readiness to stopEvery visitCompleted todayAbout ten a day; thinking about a quit date

Goal progress:

Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Twelve-week review in two weeks with potassium, creatinine, urine albumin, liver tests, PEth, AUDIT, PHQ-9 and GAD-7. Counseling weekly. The clinic or 988 at any hour. Next scheduled visit 2026-10-27: twelve-week review: kidney function after the SGLT2 inhibitor, urine albumin, liver tests, AUDIT, mood, safety and the plan ahead. [S]